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TRANSLATIONAL RELEVANCE 
 
Patients with colorectal cancer who receive the EGFR-targeted antibodies 
cetuximab or panitumumab usually develop resistance within several months 
of initiating therapy. The emergence of mutations in KRAS, NRAS, and BRAF 
is associated with acquired resistance to EGFR blockade. Interestingly, cells 
with these mutations often represent a small fraction of the resistant tumor 
mass, suggesting that non-mutant cells can also survive the treatment. We 
report that cells that have acquired resistance to cetuximab can protect 
sensitive cells through increased secretion of the EGFR ligands TGF-α and 
amphiregulin. Hence, we have unveiled a paracrine supportive network that is 
potentially amenable to therapeutic intervention. Blockade of TGF-α and 
amphiregulin could improve therapies based on EGFR-directed antibodies.  
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ABSTRACT 
 
Purpose: Targeted inhibition of EGFR with the monoclonal antibodies 
cetuximab or panitumumab is a valuable treatment for RAS wild type 
colorectal cancers. The efficacy of EGFR blockade is limited by the 
emergence of acquired resistance often attributed to secondary KRAS 
mutations. Remarkably, tumor biopsies from resistant patients show that only 
a fraction of the resilient cells carry KRAS mutations. We hypothesized that a 
paracrine crosstalk driven by the resistant subpopulation may provide in trans 
protection of surrounding sensitive cells. 
 
Experimental design: Conditioned medium assays and three 
dimensional co-cultures were used to assess paracrine networks between 
cetuximab sensitive and resistant cells. Production of EGFR ligands by cells 
sensitive to cetuximab and panitumumab was measured. The ability of 
recombinant EGFR ligands to protect sensitive cells from cetuximab was 
assessed. Biochemical activation of the EGFR signaling pathway was 
measured by western blotting. 
 
Results: CRC cells sensitive to EGFR blockade can successfully grow 
despite cetuximab treatment when in the company of their resistant 
derivatives. Media conditioned by resistant cells protect sensitive parental 
cells from cetuximab. EGFR blockade triggers increased secretion of TGFα 
and amphiregulin. Increased secretion of ligands by resistant cells can sustain 
EGFR/ERK signaling in sensitive cells.  
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Conclusions: CRC cells that develop resistance to cetuximab and 
panitumumab secrete TGF-α and amphiregulin, which protect the surrounding 
cells from EGFR blockade. This paracrine protective mechanism might be 
therapeutically exploitable.  
 
 
INTRODUCTION 
 
The epidermal growth factor receptor (EGFR) and its ligands, 
transforming growth factor alpha (TGF-α), amphiregulin (AR), epidermal 
growth factor (EGF), betacellulin (BTC), heparin-binding like EGF-factor 
(HBEGF), and epiregulin (EREG) play a central role in development of 
epithelial tumors such as colorectal cancers (CRCs) (1). More than half of 
metastatic colorectal cancers (CRCs) display mutations in members of the 
RAS signaling pathways such as KRAS, NRAS, or BRAF (2-5). A subset of 
CRCs lacking RAS-pathway mutations are intrinsically dependent on EGFR 
and the ensuing "EGFR addiction" is therapeutically tractable using two EGFR 
targeted antibodies, cetuximab and panitumumab (6). After an initial response, 
secondary resistance invariably ensues, thereby limiting the clinical benefit of 
these drugs (7, 8). We previously reported the presence of KRAS G12, G13, 
and Q61 mutated alleles in tissue biopsies from CRC patients who relapse 
after EGFR targeted therapies (9). Notably, highly sensitive methodologies 
show that ‘resistant’ KRAS mutant alleles are present only in a fraction of 
tumor cells with frequencies ranging from 0.4 to 17% (9). Several hypotheses 
could explain these findings. First, despite efforts to maximize neoplastic cell 
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content, tumor tissues often contain variable proportions of neoplastic and 
stromal cells. Secondly, it is plausible that independent subclonal cancer cell 
lineages, carrying distinct resistance mechanisms, evolve in parallel within the 
same metastatic lesion. A third possibility, explored in this work, is that a 
resistant subpopulation may sustain the growth of surrounding sensitive cells 
through the release of paracrine soluble factors. We hypothesized the 
existence of protective paracrine interactions, between RAS mutated 
(resistant) and the wild type (wt) (therapeutically sensitive) cell subpopulations.  
This hypothesis is based on evidence that cancer cells are able to generate a 
plethora of growth factors, thus achieving, in some instances, complete 
independence from externally provided ligands (10). Furthermore, it has been 
previously shown that ligands for receptor tyrosine kinases can sustain 
resistance to targeted therapies. For example, hepatocyte growth factor 
(HGF), the activating ligand for the MET receptor, can protect lung cancer 
cells from the effect of EGFR inhibitors such as erlotinib and gefitinib (11, 12). 
Similar effects can be promoted by TGF-β and IL6 (13). 
 
 
METHODS 
 
Generation of resistant cells 
The DiFi and OXCO-2 CRC cell lines were received from Dr. J. Baselga in 
November 2004 (Oncology Department of Vall d'Hebron University Hospital, 
Barcelona, Spain) and Dr. V. Cerundolo in March 2010 (Weatherall Institute of 
Molecular Medicine, University of Oxford, UK), respectively. The LIM1215 
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parental cell line (14) was obtained from Prof. Robert Whitehead, Vanderbilt 
University, Nashville, with permission from the Ludwig Institute for Cancer 
Research, Zurich, Switzerland. The genetic identity of all cell lines was 
confirmed by STR profiling (Cell ID, Promega) no longer than six months 
before execution of the experiments. Cetuximab-resistant derivatives of 
LIM1215, OXCO-2 and DiFi cell lines were generated as described in our 
previous publications (9, 15). Briefly, cells were cultured in RPMI, ISCOVES, 
(Sigma) and F12 (Gibco) for LIM1215, OXCO-2 and DiFi, respectively. Cells 
were treated with increasing concentrations of cetuximab (1, 5, 50 µg/ml for 
DiFi and 1, 5, 50, 200 µg/ml for LIM1215 and OXCO-2) until resistance was 
achieved as per Fig. 1A. The cetuximab concentration was escalated every 3 
to 4 passages. Resistant derivatives were subsequently cultured in their 
respective media with 200 µg/ml of cetuximab for LIM1215-R, OXCO-2-R and 
50 µg/ml of cetuximab for DiFi-R. 
 
DNA sequence analysis 
Mutational analysis was performed as described before (9). Briefly, DNA 
was extracted, using Wizard SV genomic DNA Purification System (Promega). 
PCR amplifications were performed using 0.25 mmol/L deoxynucleotide 
triphosphates, 1 µmol/L each of the forward and reverse primers, 6% DMSO, 
1x PCR reaction buffer, 0.05 unit/μL Platinum Taq and 1 ng/μL genomic DNA 
(Invitrogen/Life Technologies). Primer sequences were previously reported 
(15). PCR products were purified using AMPure (Agencourt Bioscience Corp., 
Beckman Coulter S.p.A, Milan, Italy). Cycle sequencing was carried out using 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems, Foster 
Research. 
on July 1, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 10, 2014; DOI: 10.1158/1078-0432.CCR-14-0774 
7 
 
City, CA). Sequencing products were purified using CleanSeq (Agencourt 
Bioscience, Beckman Coulter) and analyzed on a 3730 DNA Analyzer, ABI 
capillary electrophoresis system (Applied Biosystems). Sequence traces were 
analyzed using the Mutation Surveyor software package (SoftGenetics, State 
College, PA). 
 
Cell proliferation assays 
The proliferation assays were performed by seeding 2000 cells/well in 96 
well plates in 100 μl of media. After overnight incubation, 100 μl of media was 
added with a titrated concentration of cetuximab to achieve final 
concentrations between 0 and 500 μg/ml. Cell viability was assessed by ATP 
content using the CellTiter-Glo luminescent assay (Promega). Measurements 
were recorded using Victor-X4 plate reader (PerkinElmer). Treated cells were 
normalized to the untreated. Data points represent mean +/- SD of three 
independent experiments. 
In stimulation experiments, the proliferation assay described above was 
modified. The cetuximab titrated media added on the second day was 
supplemented with recombinant human amphiregulin or TGF-α (Abcam, AR 
[ab104355] TGF-α [ab9587]) at the following concentrations respectively: 0, 
5,000 and 10,000 pg/ml and 0, 100, 200, 400 pg/ml. Cell viability was 
assessed by ATP content using the CellTiter-Glo luminescent assay 
(Promega). Measurements were recorded using Victor-X4 plate reader 
(PerkinElmer). Treated wells were normalized to untreated. Data points 
represent mean ± SD of three independent experiments. 
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Conditioned medium assay 
The conditioned medium assay (CMA) was performed in two phases. In 
the first phase, 1.5 million of sensitive or resistant cells were seeded in 100 
mm culture dishes in 10 ml of their respective medium supplemented with 
cetuximab at a drug concentration of 2, 1, 0.5 μg/ml for LIM1215, OXCO2 and 
DiFi, respectively. Medium was conditioned for 72 hours. In the second phase, 
sensitive cells were seeded in 6 well plates at a density of 5x104/well. After 
overnight incubation, attached cells were washed with PBS and covered with 
4 ml of media prepared from half conditioned and half fresh medium (Fig. S1). 
After 6-7 days of incubation, the viability of sensitive cells was assessed by 
ATP content using the CellTiter-Glo luminescent assay (Promega). 
Luminescence was measured by Victor-X4 plate reader (PerkinElmer). 
Results were normalized to viability of sensitive cells incubated with 
conditioned media from sensitive cells with cetuximab. Data points represent 
mean ± SD of three independent experiments. 
 
Three dimensional co-culture assays 
For the three dimensional co-culture experiment in soft agar, sensitive 
and resistant derivatives of OXCO-2 were labeled by lentivirus mediated 
transduction with DsRED and GFP. The reporter plasmid vector, pLemiR 
(Empty Vector) with DsRED (Open Biosystems) was packaged into lentiviral 
particles using HEK293 cells. The GFP reporter lentivirus was obtained as 
ready to use lentiviral particles LVP300 (Amsbio). A total of 105 cells/well were 
seeded in a 6-well plate (Costar) and infected the following day with lentiviral 
particles. After four days of incubation, cells were checked for DsRED and 
Research. 
on July 1, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 10, 2014; DOI: 10.1158/1078-0432.CCR-14-0774 
9 
 
GFP reporter gene expression by fluorescence microscopy. Fluorescent 
populations were expanded and subjected to puromycin (DsRED) and 
neomycin (GFP) selection for one week. After selection, cells were expanded 
and banked in liquid nitrogen until use. One million of fluorescent labeled cells 
were seeded in 60 mm dishes, including parental (P-DsRED), resistant (R-
GFP) or the mixture of both populations. Cells were incubated overnight and 
then detached by short trypsinization, counted, and seeded in soft agar. The 
soft agar assay was performed in 12 well plates (Costar) where the bottom of 
the wells was covered with culture medium enriched with agarose (1%). A 
total of 20,000 cells/well were seeded in 1 ml of 0.6% agarose enriched 
culture medium. During the two weeks of incubation, 100 µl of medium with or 
without cetuximab (1 µg/ml) was added every 3-4 days for nutrition and 
evaporation compensation. After incubation for two weeks, approximately 120 
colonies were counted in each well, and their colors were recorded by 
fluorescence microscopy. Images were acquired with LEICA DMI3000 B 
microscope and fluorescence images were overlaid by Adobe Photoshop CS2 
software. Data points represent mean ± SD of two independent experiments. 
 
Measurements of EGFR ligands by ELISA 
Measurements of ligands’ concentrations were performed by ELISA. The 
respective media for the three cell line models was conditioned as for CMA 
(above) with and without cetuximab. After 72 hours of incubation, media were 
collected, centrifuged, aliquoted and stored at -20oC for up to 2 weeks. Each 
aliquot was thawed and used only once. Ligand measurements were 
performed by R&D DuoSet ELISA assays, DY239 (TGF-α), DY262 (AR), 
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DX236 (EGF), DY259 (HB-EGF), DY377 (NRG1), DY294 (HGF) in 96-well 
format according to manufacturer’s instructions. Well washing was performed 
with WellwashTM Versa Microplate Washer instrument (Thermo Scientific). 
Dual absorbance spectra were measured according to manufacturer’s 
instructions using Victor-X4 plate reader (PerkinElmer). Data points represent 
mean ± SD of three independent experiments. 
Ligand concentration measurements in the time course experiments were 
recorded using the same ELISA DuoSet system. Sensitive or resistant 
derivative cells were seeded in six 100 mm dishes at a density of 1.5x106/dish 
and incubated overnight. At time 0, cells were detached and counted using a 
Coulter particle counter (Beckman Coulter). After 6, 12, 24, 48, and 72 hour 
time points, cells were detached and counted and conditioned media was 
collected, aliquoted, and stored at -20ºC for up to two weeks. Ligand 
concentrations in non-conditioned media (for time point 0) or conditioned 
media (for other time points) were normalized to the number of counted cells 
and expressed as pg/106 cells according to formula (L*V/N)*106, where L= 
measured ligand concentration (pg/ml), V= total volume of media (ml), and N= 
number of counted cells. Data points represent mean +/- SD of two 
independent experiments. 
 
Western blot analysis 
Biochemical activation of EGFR and its downstream effector ERK1/2 by 
conditioned media was assessed by western blot. Two million cells were 
seeded in 100 mm dishes with 10 ml of respective media containing 1% of 
serum with and without cetuximab (2 μg/ml). After 72 hours of incubation, the 
Research. 
on July 1, 2014. © 2014 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 10, 2014; DOI: 10.1158/1078-0432.CCR-14-0774 
11 
 
conditioned media was used for stimulation of 7 million serum-starved (24 
hours) parental cells. After 30 minutes of stimulation, cells were lysed with 
cold lysis buffer (NaCl 150 mM, triton-x100 1%, EDTA 5 mM, glycerol 10%, 
EGTA 2 mM, HEPES 500 M) containing protease inhibitors (aprotinin, 
leupeptin, pepstatin, soybean trypsin inhibitor, and phenylmethylsulfonyl 
fluoride) and phosphatase inhibitors (sodium orthovanadate and sodium 
fluoride). Western blot detection was done by enhanced chemiluminescence 
(GE Healthcare). The following antibodies were used for western blotting: 
anti-phospho-p44/42 ERK (Thr 202/Tyr204), (Cell Signaling Technology); anti-
p44/42 ERK (Cell Signaling Technology); anti-P-MEK1/2 (Ser 217/221), anti-
MEK1/2, anti-EGFR (clone13G8, Enzo Life Sciences); anti-phospho EGFR 
(Tyr 1068) (Cell Signaling Technology); anti-vinculin (Sigma-Aldrich). 
 
Statistical analysis 
All statistical analyses were completed using the Student’s t test (two 
tailed). P ≤ 0.05 was considered significant. 
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RESULTS 
 
CRC cell lines that develop resistance to EGFR-directed therapy exert 
paracrine in trans protection of sensitive cells  
 
We studied three CRC cell lines (LIM1215, OXCO-2, and DiFi) that are 
highly sensitive to cetuximab, from which we previously derived resistant 
subpopulations by continuous exposure to the antibody (9, 15) (Fig.1A). While 
the parental cells were wt for KRAS, NRAS, and BRAF, resistant derivatives 
acquired several mutations. Cetuximab resistant LIM1215 (LIM1215-R) 
displayed KRAS pG12R, KRAS pK117N, NRAS pG12C variants, while 
OXCO-2 resistant (OXCO-2-R) acquired KRAS pG12D and BRAF pV600E 
alleles (9, 15). Resistant subpopulations of DiFi (DiFi-R) developed a ~50 fold 
amplification of wt KRAS and lost amplified wt EGFR (9). 
To investigate whether the resistant cells, in addition to the genetic 
alterations described above, also developed the ability to create a permissive 
microenvironment for sensitive cells, we performed a conditioned medium 
assay (CMA) experiment (Fig. S1). Initially, resistant and sensitive populations 
conditioned their respective culture medium in the presence of cetuximab for 
72 hours as described in the methods. Subsequently, sensitive cells were 
seeded in a 1:1 ratio of conditioned media (CM) and fresh culture media to 
avoid the negative effect of partial depletion of CM (Supplementary Fig. S1). 
After one week, the supernatant from resistant derivatives increased the 
viability of parental cells by two-fold when compared to the effect induced by 
CM collected from the corresponding sensitive cells (Fig. 1B). The influence of 
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CM from resistant derivatives was evident in all three cell models. This data 
supports the hypothesis that resistant cells carrying genetic alterations in the 
RAS pathway produce paracrine-acting factors that could shield sensitive wt 
cells from the anti-EGFR antibody cetuximab. 
 
Cetuximab resistant cells create a permissive microenvironment for 
sensitive cells  
To directly observe the protective influence of resistant (R) cells on sensitive 
(S) cells, we developed a 3D culture system in which S and R cell populations 
differentially expressed the fluorescent markers, DsRED in S (RED-S) and 
GFP in R (GREEN-R). OXCO-2 cells were most conducive for the 
experiments as they were readily transduced with the lentivirus and formed 
spheroid colonies. After a two-week incubation period, spheroids were 
documented by light and fluorescence microscopy (Fig. 2A and B). As 
expected the RED-S population did not produce viable colonies in the 
presence of cetuximab. In contrast, the GREEN-R population readily formed 
colonies. Interestingly, when mixed colonies were generated by seeding RED-
S and GREEN-R populations in a 1:1 ratio, RED-S cells were successfully 
growing together with GREEN-R derivatives despite cetuximab (Fig. 2B). To 
provide quantitative measurements, colonies were counted and grouped 
according to their colors. In the presence of cetuximab, there was an increase 
of dual colored colonies and a small number of RED-S (~90% RED-
S/GREEN-R vs ~10% RED-S) (Fig. 2C). The small number of RED-S 
colonies can be potentially explained by incomplete fluorescent labeling of 
cells, resulting in a portion of unlabeled cells in the spheroids. Incomplete 
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labeling is evident in the micrographs (Fig. 2B), where portions of spheroids 
are neither red nor green. 
In summary, the 3D assay enabled us to directly observe proliferation of S 
cells together with R derivatives in the presence of cetuximab. Proliferation of 
S cells despite cetuximab treatment can only be attributed to the presence of 
the R cells. We conclude that resistant cells substantially modified the intra-
colony microenvironment making it permissive for proliferation of sensitive 
cells, despite cetuximab treatment. 
 
Cetuximab resistant cells secrete TGF-α and amphiregulin, whose 
production is further increased by cetuximab treatment 
The experiments above suggest that protective paracrine interactions 
could be mediated by soluble factors. To identify such factors, media 
conditioned by S and R cells from each of the three cell models (LIM1215, 
OXCO-2, DiFi) were investigated using ELISA assay. The presence of the 
EGFR ligands TGF-α, amphiregulin, EGF, HB-EGF, and NRG1 was 
measured after 72 hours of incubation (Fig. 3A and B and Fig S2). Since HGF, 
the MET receptor ligand, has been previously shown to confer resistance to 
EGFR inhibitors (16), its concentration was also evaluated. 
Media conditioned by R populations revealed significantly higher 
concentrations of TGF-α and amphiregulin compared to their S counterparts, 
even when not exposed to cetuximab (Fig. 3A and B). However, when cells 
were treated with cetuximab, the ligand secretion was, at least partially, cell-
type specific. In the presence of cetuximab, sensitive LIM1215 and OXCO-2 
significantly increased secretion of TGF-α, while DiFi did not. More 
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importantly, intrinsically higher secretion of TGF-α by R cells was further 
stimulated by cetuximab treatment in all three cell models (Fig. 3A). On the 
other hand, the over-secretion of amphiregulin in R cells did not further 
increase under cetuximab treatment (Fig. 3B). No differences in the 
concentration of other assessed ligands were noted (Fig. S2) 
In the previous assay, ligand levels were measured after 72 hours of 
incubation. Therefore, only the final cumulative concentration was revealed. 
These results may be influenced by differences in cell numbers and the 
temporal heterogeneity of secretion. To further analyze the production of 
TGF-α and amphiregulin by S and R populations, we performed a time course 
experiment and normalized ligand concentration to the number of cells in two 
cell models (LIM1215 and DiFi). Consistent with the above observations, 
cetuximab triggered an increased secretion of TGF-α in both LIM1215-S and 
R cells (Fig. 3C). In contrast, cetuximab treatment did not increase TGF-α 
secretion in DiFi S cells but did stimulate its secretion in the R derivatives (Fig. 
3D). On the other hand, secretion of amphiregulin increased in DiFi S when 
exposed to cetuximab (Fig. 3F). Notably, in both LIM1215 and DiFi, R cells 
treated with cetuximab secreted up to 3 fold more TGF-α and amphiregulin in 
comparison to their sensitive counterparts (Fig. 3C-F). When drug-treated 
LIM1215 and DiFi cells are compared to untreated cells, cetuximab triggered 
a greater than 3-fold increase of TGF-α levels in both S and R cells 
(Supplementary Fig. S3A and B). These experiments demonstrate that 
differential secretion profiles of TGF-α and amphiregulin are not due to 
different cell numbers, but reflect increased secretion of ligands by resistant 
cells in response to EGFR blockade. 
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Mutant KRAS G12R knock-in cells exert paracrine protection from 
cetuximab 
Our results provide direct evidence for increased production of EGFR 
ligands by cetuximab resistant derivatives, and these ligands can sustain in 
trans protection of sensitive cells. As discussed above, the development of 
resistance in patients is associated with the emergence of 'secondary' KRAS 
genetic alterations. To formally link the acquisition of KRAS mutations to the 
increased secretion of ligands, we exploited LIM1215 cells in which a mutant 
KRAS allele (G12R) was introduced in the endogenous KRAS locus making 
them resistant (9). Medium conditioned by the knock-in (mutant) population 
had protective properties similar to that of cells, which had acquired 
resistance (Fig. S4A), and cetuximab triggered increased secretion of TGF-α 
(Fig. S4B and C). 
 
TGF-α and amphiregulin protect from cetuximab 
While these data point to paracrine protection against cetuximab, they do 
not formally prove that EGFR ligands are directly responsible for this effect. 
Accordingly, we implemented forward biological experiments in which 
proliferation assays were performed in the presence of recombinant TGF-α 
and amphiregulin. In all cell models, the addition of TGF-α reduced the 
inhibitory effect of cetuximab in a dose dependent manner (Fig. 4A), albeit to 
a lesser extent in OXCO-2. In contrast, amphiregulin was protective only in 
DiFi (Fig. 4B). The cell line specific responsiveness to EGFR ligands is 
intriguing and may reflect differences in EGFR signaling dependency. For 
example, DiFi are extremely sensitive to cetuximab mediated EGFR blockade 
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likely due to EGFR gene amplification that results in protein overexpression 
(17-19). 
 
Media conditioned by cetuximab resistant cells sustains ERK signaling 
in sensitive cells 
To provide a mechanistic link between paracrine factors produced by 
resistant cells and increased resilience of sensitive cells to cetuximab, we 
studied whether and how EGFR intracellular signaling was affected by 
conditioned media. As a model, we used parental S LIM1215 that were serum 
starved and then stimulated with conditioned media from S parental or R 
derivatives in the presence or absence of cetuximab. Untreated and TGF-α 
stimulated sensitive cells served as negative and positive control, respectively. 
After 30 minutes of stimulation, the activation of EGFR downstream signaling 
was determined by western blot. Media conditioned by resistant derivatives 
fostered greater phosphorylation of EGFR and ERK1/2 compared to media 
derived from parental cells (Fig. 5). This indicates that paracrine effectors 
could sustain EGFR signaling in sensitive cells. 
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DISCUSSION 
Altogether our data indicates that CRC cells that develop resistance 
through RAS pathway mutations produce significantly higher levels of TGF-α 
and amphiregulin. In patients undergoing treatment based on EGFR directed 
monoclonal antibodies, tumor cells are continuously exposed to cetuximab for 
several months. Our in vitro data suggest that tumor cells initially sensitive to 
cetuximab respond to EGFR blockade by increasing the secretion of TGF-α 
and amphiregulin. Furthermore, we provide evidence that acquired resistance 
to cetuximab involves a paracrine network driven by EGFR ligands. It is 
conceivable that increased secretion of EGFR ligands may also be a 
mechanism of immediate response to EGFR blockade driven by intracellular 
pro-survival signaling cascades. The ensuing signaling network would then be 
maintained after the acquisition of EGFR downstream pathway mutations (in 
RAS and other effectors). Overall, our results support the possibility of 
paracrine in trans protection of sensitive cells by their mutated resistant 
derivatives.  
Microenvironmental concentrations of EGFR ligands in tumor tissue may 
very well rise to high enough levels to counteract the inhibitory concentration 
of cetuximab (20). Speculatively, when the balance between anti- and pro-
proliferative effects of cetuximab and EGFR ligands, respectively, is tipped 
toward proliferation of sensitive cells, there is little reason for resistant cells to 
increase their numerical proportion to achieve tumor resistance as a whole. 
Just as the anti-EGFR antibody concentration gradients are established in 
tumor tissue (21), ligand concentration gradients are equally probable, 
radiating outward from resistant cells. Proliferation of sensitive cells would 
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therefore be limited to permissive zones within the tumor. Amphiregulin and 
TGF-α binding to EGFR cause longer retention time of the receptor on the 
surface of the plasma membrane and can redirect EGFR to the recycling 
pathway rather than to proteasomal degradation (22, 23). This can potentially 
strongly enhance the pro-proliferating effect of the modified/protective 
microenvironment. 
Previous reports correlated increased mRNA expression of amphiregulin 
and EREG in metastatic CRC specimens with response to cetuximab 
treatment (24, 25). These clinical studies support the hypothesis that KRAS 
wild type CRC may respond well to anti-EGFR therapy as a result of 
dependence on EGFR pathway signaling. In turn, EGFR dependence in RAS 
wild type tumors may be mediated by expression of EGFR ligands that trigger 
constitutive receptor activation. Instead, in cells that become refractory to anti-
EGFR therapy, abnormal production of ligands overcomes the effects of 
cetuximab or panitumumab. It should be also noted that in our work we 
measured secreted protein ligands, while the studies mentioned above 
assessed mRNA gene expression (24, 25). Accordingly, protein levels of 
secreted ligands may more pertinently evaluate their protective potential 
towards the surrounding sensitive cells than ligands mRNA levels in the 
original cancerous tissue. Of further note, in previous studies the predictive 
effect was not noted in patients with KRAS mutations, but only in KRAS wild 
type patients (24). In support of our preclinical work, Loupakis and colleagues 
have reported increased levels of circulating EGFR ligands in the plasma of 
mCRC patients at the time of the radiological progression to cetuximab and 
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irinotecan, suggesting their potential role as a mechanism of acquired 
resistance to drug treatment (26).  
KRAS activating mutations were previously associated with increased 
production of EGFR ligands (27) and increased radiation resistance due to 
paracrine/autocrine protection (28). The ability of amphiregulin to sustain 
growth of cancer cells was previously reported in association with low serum 
in vitro where neutralization of amphiregulin in conditioned media inhibited cell 
growth (29-31). Studies of the non-transformed breast derived cell line MCF-
10A transduced with inducible RAF/estrogen/GFP fusion protein have shown 
that RAF activation results in high ERK activation (32). Sustained ERK 
signaling was shown to boost secretion of the EGFR ligands, HB-EGF, TGF-α 
and amphiregulin, which, in turn, activated EGFR in an autocrine fashion (32). 
Most interestingly, conditioned medium from RAF transduced cells, 
successfully prevented anoikis in the original parental MCF-10A population 
(32).  
Recent studies established intratumor heterogeneity within geographically 
distinct portions of tumors (33). It is also accepted that intraclonal genetic 
diversity and genomic instability provides a substrate for therapeutic clonal 
Darwinian selection of the fittest (34, 35). However, Darwinian selection does 
not explain the low prevalence of RAS/RAF mutated resistant cells in relapsed 
CRC tumors. The in trans paracrine protection effect described here offers at 
least a partial explanation for this phenomenon. Conceptually, targeted 
therapy may offer a selective advantage to resistant cells, but paracrine 
protection of sensitive subpopulations could significantly widen the selective 
bottleneck (Fig 6). This could help preserve initial clonal heterogeneity at the 
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time of relapse and substantially increase it during subsequent tumor 
regrowth. The ability of low frequency KRAS mutations to persist through anti-
EGFR therapy and sustain surrounding sensitive cells suggest the importance 
of improving the sensitivity of RAS mutation detection, as it is possible that 
low prevalence mutations may affect (the duration of) responses in patients 
(36). 
The persistence of sensitive cells could have clinical implications for 
further lines of therapy. Indeed, when CRC patients suspend anti-EGFR 
therapy, they are often offered an additional line of chemotherapy with agents 
that act via an EGFR-independent pathway. It is possible that the subsequent 
treatments allow the outgrowth of sensitive cells over resistant clones when 
the pressure on the EGFR pathway is relieved. The ultimate outcome would 
be the regrowth of neoplastic cells sensitive to EGFR treatment. In support of 
this hypothesis, a clinical report recently described successful re-challenging 
with EGFR targeted monoclonal antibodies of patients who had become 
refractory to cetuximab and were subsequently treated with additional lines of 
therapy (37). We previously reported that CRC cells that develop KRAS 
mutations as a mechanism of resistance to EGFR blockade are sensitive to 
the combination of EGFR-MEK blockade (15). It is possible that cells in which 
the ligand paracrine network contributes to anti-EGFR resistance may be 
equally sensitive to this combination and this aspect should be further 
explored. 
The concept of protective paracrine interactions between genetically 
distinct subclonal cell populations is most likely transferable to other cancer 
types and to acquired resistance against other types of therapy. We believe 
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that additional research into perturbation of paracrine interactions, such as by 
ligand neutralization, could lead to improvement of existing therapies. 
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FIGURE LEGENDS 
Figure 1 
Cells with acquired resistance to cetuximab can protect their drug-sensitive 
parental counterparts in a paracrine fashion. (A), comparison of sensitive and 
resistant LIM1215, OXCO-2 and DiFi cells. Cell viability was assayed by the 
ATP assay. Data points represent the mean ± SD of three independent 
experiments. (B), conditioned medium assay (CMA) performed by transfer of 
conditioned media with cetuximab (CTX) from sensitive (S, orange) or 
resistant (R, green) cells (1:1 – fresh: conditioned) on top of sensitive cell 
population. Cell viability is normalized to sensitive cells incubated with media 
conditioned by sensitive cells with cetuximab (LIM1215: 2 µg/ml, OXCO-2: 1 
µg/ml and DiFi: 0.5 µg/ml). Symbols and bars, mean ± SD of three 
independent experiments. 
 
 
Figure 2. 
Cetuximab sensitive parental cells proliferate in 3D culture together with their 
resistant derivatives in the presence of cetuximab. (A), bright field 
micrographs of OXCO-2 sensitive (S), resistant (R) and co-culture (S:R-1:1) 
colonies in 3D culture without and with 1 ug/ml cetuximab (CTX). Scale bar 
represents 250 µm, magnification 25x. (B), bright field and fluorescence 
micrographs of OXCO-2 sensitive (RED-S) and resistant (GREEN-R) 
spheroid colonies in 3D culture. Scale bar represents 62 µm, magnification 
250x. (C), count of sensitive (S) and double colored (S/R) colonies observed 
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after 2 weeks of incubation in 3D culture in the presence or absence (control) 
of CTX. Symbols and bars, mean ± SD of two independent experiments. 
 
 
Figure 3. 
Cetuximab (CTX) resistant cells secrete higher levels of EGFR ligands than 
sensitive cells. Ligand secretion is stimulated by CTX treatment in a cell-type 
dependent manner. (A and B), TGFα and amphiregulin (AR) levels in media 
conditioned by sensitive and resistant LIM1215, OXCO-2, and DiFi cells after 
72 hours of incubation with or without CTX. Error bars represent the mean ± 
SD of three independent experiments. * p ≤ 0.05, **p < 0.01. (C-F), secretion 
of TGFα and AR by LIM1215 and DiFi sensitive and resistant cells during a 72 
hour time course with and without CTX treatment. Ligand levels were 
normalized to number of cells for each time point and expressed as pg/106 
cells. Error bars represent mean ± s.d of two independent experiments. S: 
sensitive, R: resistant, CTX: CTX treated. * p ≤ 0.05, between cell populations 
in the same column (Student’s t test, two tailed). 
 
 
Figure 4 
Cetuximab (CTX) sensitivity in sensitive cells can be overcome by exogenous 
EGFR ligands. (A and B), cell proliferation assay comparing the effects of 
recombinant human TGFα and amphiregulin (AR) on LIM1215 (left), OXCO-2 
(middle), and DiFi (right) sensitive parental cells to CTX treatment. Error bars 
represent mean ± SD of three independent experiments. 
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Figure 5 
Conditioned medium (CM) from resistant cells sustains ERK signaling. 
Western blot analysis of protein expression after 30 minute stimulation of 
LIM1215 sensitive cells with the indicated treatments. CONTROL: serum free 
media; CTX: serum free media with 2 µg/ml cetuximab, TGFα: serum free 
media with 5 ng/ml TGF-alpha; CM-S CTX: CM from sensitive cells treated 
with 2 µg/ml CTX; CM-R CTX: CM from resistant cells treated with 2 µg/ml 
CTX; CM-S CTX later: CM from sensitive cells with CTX added after 
conditioning; CM-R CTX later: CM from resistant cells with CTX added after 
conditioning; CM-S: CM from sensitive cells, CM-R: CM from resistant cells. 
Asterisks indicate the bands to be compared in individual exposures. 
 
 
Figure 6 
Conceptual representation of the impact of intercellular paracrine protection 
during cetuximab therapy in colorectal cancer. 
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